E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pruritus in patients with burns |
|
E.1.1.1 | Medical condition in easily understood language |
Itch in patients with burns |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10006799 |
E.1.2 | Term | Burns NOS |
E.1.2 | System Organ Class | 100000004863 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037090 |
E.1.2 | Term | Pruritus cutaneous |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate whether doxepin hydrochloride 5% cream is more effective in reducing pruritus in patients with burns than standard treatment. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate whether patients treated with doxepin hydrochloride 5% cream compared to standard treatment:
- have a better quality of life
- have less erythematous scars |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with healed burns and itch. Patients are divided into four groups i.e.
1) patients with partial thickness wounds, not exceeding 4 months postburn
2) patients with full thickness wounds, not exceeding 4 months postburn
3) patients with partial thickness wounds between 4 months postburn and 3 years postburn
4) patients with full thickness wounds between 4 months postburn and 3 years postburn
• Itch intensity as assessed by VAS score greater than or equal to 3
• Patients treated in one of the three Dutch burn centres
• Patients aged 18 years or older |
|
E.4 | Principal exclusion criteria |
- Inability to give informed consent by patient or legal representatives
- Inability to understand and fill in VAS scores and quality of life/pruritus assessment questionnaires, as judged by the treating physician
- (Active) cutaneous or systemic disease causing itch
- Any disease or condition which, according to the physician's judgement, is associated with adverse effects using doxepin, that is:
Contra-indications Tavegil
- hypersensitivity to clemastine or other arylalkylamine antihistamines, or any of the excipients
- porphyria
Precautions Tavegil:
- fructose intolerance
- narrow-angle glaucoma
- stenosing peptic ulcer
- pyloroduodenal obstruction
- prostatic hypertrophy with urinary retention and bladder neck obstruction
- galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- pregnancy and lactation
Contra-indications Xepin:
- hypersensitivity to any of its components.
Precautions Xepin
- glaucoma
- a tendency to urinary retention
- severe liver disease
- mania
- severe heart disease (including cardiac arrythmias)
- pregnancy and lactation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main study parameters are change in mean pruritus intensity; VAS scores from baseline during 12 weeks of treatment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
VAS pruritus: 0 weeks (inclusion), day 1-13 (daily), 2 weeks, 6 weeks, 12 weeks (end of study) |
|
E.5.2 | Secondary end point(s) |
Secondary study parameters include quality of life as measured by the SF-36 questionnaire, characteristics of the itch as measured by the Burn Itch Questionnaire, reported somnolence and response of erythema.
Other study parameters include use of escape moisturizer and use of pressure garments. Furthermore age, gender, location of burn wound, post-burn period, total body surface area, size of itching area, length of period of itch, treatment before inclusion (if applicable) will be recorded. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- SF-36 questionnaire: 0 weeks (inclusion), 12 weeks (end of study)
- Burn Itch Questionnaire: 0 weeks (inclusion), 12 weeks (end of study)
- somnolence: 0 weeks (inclusion), day 1-13 (daily), 2 weeks, 6 weeks, 12 weeks (end of study)
- erythema: 0 weeks (inclusion), 2 weeks, 6 weeks, 12 weeks (end of study)
- use of escape moisturizer: 0 weeks (inclusion), day 1-13 (daily), 2 weeks, 6 weeks, 12 weeks (end of study)
- use of pressure garments: 0 weeks (inclusion), day 1-13 (daily), 2 weeks, 6 weeks, 12 weeks (end of study) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |